Novartis AG - Ebitda

Novartis AG's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Ebitda" stands at 22.04 Billion United States Dollars for the trailing twelve months (TTM) period ending 06/30/2026, the lowest value since 06/30/2025.

Novartis AG's second quarter result of 5.83 Billion USD for the item "Ebitda" represents an increase of 10.93 percent compared to it's first quarter result.

Also, Novartis AG's second quarter result of 5.83 Billion USD for the item "Ebitda" represents a decrease of -4.08 percent compared to it's second quarter result of last year.

Looking again at the trailing twelve months series (TTM), Novartis AG's second quarter result of 22.04 Billion USD for the item "Ebitda" represents a decrease of -1.11 percent compared to it's first quarter result.


Regarding the One-Year-Change of the series, the current value constitutes a decrease of -2.60 percent compared to the value the year prior.
The 1 year change in percent is -2.60.
The 3 year change in percent is 31.15.
The 5 year change in percent is 20.90.
The 10 year change in percent is 56.74.

The Serie's long term average value is 17.99 Billion United States Dollars. It's latest available value, on 06/30/2026, is 22.53 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 09/30/2018, to it's latest available value, on 06/30/2026, is +69.70%.
The Serie's change in percent from it's maximum value, on 12/31/2021, to it's latest available value, on 06/30/2026, is -33.34%.